1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Brooks Laboratories Limited

Brooks Laboratories Limited

BROOKS.NS
Brooks Laboratories LimitedIN flagNational Stock Exchange of India
69.90
INR
-0.61
- -
2.06BMarket Cap
Brooks Laboratories Limited
BROOKS.NS
(National Stock Exchange of India)

Recent

price

69.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
44.16
28.61
40.87
43.5
43.47
40.82
29.35
28.42
39.73
38.88
30.88
36.12
25.29
30.84
30.81
29.12
29.16
Revenue per Share
5.79
4.51
3.64
3.69
4.83
5.42
0.85
-7.05
-10.69
-13.71
-7.77
-7.74
-8.46
-7.65
-3.72
8.35
8.36
Basic EPS, GAAP
2.55
-12.14
1.72
4.42
-9.12
-14.18
-4.11
-6.08
-4.27
-6.73
-0.46
-24.32
-6.06
-4
0.64
1.97
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
15.9
17.37
24.59
28.36
29.59
37.29
38.14
31.09
33.31
17
4.35
0.43
2.27
-4.86
-7.16
10.01
10.02
Book Value per Share
16.33
46.56
53.77
57.29
56.84
64.54
65.44
58.4
75.64
55.18
31.45
53.59
29.86
25.57
36.61
41.66
41.71
Tangible Book Value per Share
12
20
20
20
20
20
20
20
14
18
25
25
25
26
27
29
29
Basic Weighted Avg Shares
525
561
801
853
852
800
575
557
550
691
770
901
625
790
826
857
857
Sales/Revenue/Turnover
16.57
17.52
12.1
9.02
7.22
12.79
5.86
-27.59
-22
-13.37
-8.57
-24.09
-53.7
1.83
4.04
6.38
6.38
Operating Margin (%)
6
7
8
8
11
12
17
64
65
66
71
74
70
18
16
16
16
Depreciation Expense
69
88
71
72
95
106
17
-138
-148
-244
-194
-193
-209
-196
-100
246
246
Net Income, GAAP
4.19
3.64
25.45
4.38
8.53
1.71
32.86
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
13.11
15.76
8.92
8.49
11.11
13.29
2.9
-24.79
-26.9
-35.26
-25.15
-21.44
-33.44
-24.8
-12.07
28.67
28.67
Profit Margin (%)
-26
278
416
367
326
16
-24
-98
-157
-79
-163
123
-54
80
110
156
156
Working Capital
9
- -
- -
- -
- -
3
107
166
139
119
144
101
6
4
14
21
21
LT Debt
194
913
1,054
1,123
1,114
1,265
1,283
1,145
1,052
984
791
1,343
740
656
981
1,227
1,227
Total Equity
31.15
15.73
7.27
6.72
5
8.22
1.65
- -
- -
- -
- -
- -
- -
- -
- -
4.62
4.62
Return on Invested Capital (%)
26.22
28.22
16.94
13.94
16.91
16.56
2.7
- -
- -
- -
- -
- -
- -
- -
- -
192.84
192.84
Return on Capital (%)
42.99
33.36
17.37
13.95
16.67
16.22
2.25
-20.36
-27.65
-63.83
-94.32
-323.52
-624.12
-123.03
- -
- -
50.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
66
- -
64
LT Borrowings
1
- -
12
LT Finance Leases
11
- -
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
- -
29
Market Capitalization
3,757
2,311
1,091

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
376
- -
374
Cash, Cash Equivalents & STI
18
- -
79
Accounts Receivable, Net
252
- -
161
Inventories
77
- -
110
Total Current Liabilities
217
- -
218
Payables & Accruals
- -
- -
- -
ST Debt
66
- -
64
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.46%
17.61%
25.03%
Free Cash Flow
510.64%
1,033.57%
239.75%
Net Income, GAAP
-135.58%
-78.83%
-346.65%
Sales/Revenue/Turnover
2.57%
4.22%
3.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
157
243
217
172
790
2025
179
208
205
233
826
2026
255
235
166
202
857

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.81
-0.6
-1.51
- -
-7.65
2025
-0.94
-1.51
-0.82
-0.54
-3.72
2026
3.25
2.71
1.87
0.52
8.35

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Lasa Supergenerics Limited (LASA.NS)
Suven Life Sciences Limited (SUVEN.BO)
TransCanna Holdings Inc. (TCNAF)
Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS)
Ascend Wellness Holdings, Inc. (AAWH)
LFTD Partners Inc. (LIFD)
Business
Brooks Laboratories Limited (BROOKS.NS), a research-driven pharmaceutical contract development and manufacturing organization (CDMO), manufactures sterile injectables and oral dosage forms for pharmaceutical companies in India and internationally. The company offers dry powder injections, liquid injections, general injectables, Beta Lactam tablets, Beta Lactam injections and suspensions, oral suspensions, eye/ear drops, and cephalosporin products; it specializes in critical care formulations including carbapenems through its joint venture subsidiary Brooks SteriScience Limited. Founded in 2002 and headquartered in Mumbai, India, Brooks Laboratories operates WHO-GMP certified manufacturing facilities in Baddi, Himachal Pradesh, and Vadodara, Gujarat, with accreditations from regulatory authorities in Nigeria, Cambodia, Ivory Coast, Yemen, Vietnam, Syria, and the Democratic Republic of Congo. The company exports to markets including Venezuela, Mauritius, Colombia, Uzbekistan, Kosovo, Kenya, Latin America, and other regions in the Rest of World (ROW) and semi-regulated countries. In recent developments, Brooks Laboratories continues expansion through strategic alliances for product registrations in global markets and maintains its carbapenem business via the SteriScience joint venture, which received USFDA approval for the Vadodara facility and focuses on penetrating regulated markets such as the US, Europe, Canada, Australia, and India.